Mounjaro London 2026: The Complete Guide to Tirzepatide Weight Loss Injections at The Wellness

Medically reviewed by The Online GP by The Wellness clinical team | Last updated: April 2026

Mounjaro (tirzepatide) is the most effective licensed weight loss injection currently available in the UK, producing 15 to 22.5 percent average body weight loss over 72 weeks of treatment. It is a once-weekly injection that works on two appetite-regulating hormones (GLP-1 and GIP), making it more powerful than single-hormone medications like Wegovy or Saxenda. Private Mounjaro treatment in London ranges from £120 to £375 per month depending on the provider, with substantial differences in clinical care quality between the cheapest online pharmacy services and proper doctor-led programmes. At The Online GP by The Wellness in Marylebone, doctor-led Mounjaro treatment costs £225 to £275 per month inclusive of medication, prescription, and structured clinical monitoring, with full GMC-registered medical assessment before initiation.

This guide explains exactly how Mounjaro works, who is eligible, what results to expect, how it compares with Wegovy and other options, and why proper clinical supervision matters more than the lowest headline price. Tirzepatide is a powerful medication with real side effects and requires structured medical care to use safely and effectively.

Speak to a GMC-registered doctor today: WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com | Call 020 3951 3429

What is Mounjaro and how does it work?

Mounjaro is the brand name for tirzepatide, a once-weekly subcutaneous injection manufactured by Eli Lilly. It is licensed by the MHRA in the UK for both type 2 diabetes treatment and chronic weight management in adults. The active mechanism is dual receptor agonism: tirzepatide activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, the two major incretin hormone pathways involved in appetite, satiety, blood glucose regulation, and gastric emptying.

The dual-receptor mechanism is what makes Mounjaro fundamentally different from earlier GLP-1 medications. Wegovy, Ozempic, and Saxenda all activate GLP-1 only. Mounjaro activates both pathways, producing additive effects on appetite suppression, fullness, slower stomach emptying, and improved glucose control. The result is the highest average weight loss of any currently available licensed weight loss medication.

In practical terms, Mounjaro reduces hunger, increases satiety after smaller meals, slows the rate at which food leaves your stomach, and reduces the cognitive preoccupation with food that drives overeating in many patients with obesity. The medication does not magically burn fat. It changes the biological signalling that drives caloric intake, making it substantially easier to eat less without constant willpower depletion.

Treatment is delivered via a pre-filled KwikPen that contains 4 weekly doses. Each dose is a single subcutaneous injection into the abdomen, thigh, or upper arm, typically taken at the same time each week. Dose escalation begins at 2.5mg weekly for the first 4 weeks, then increases by 2.5mg every 4 weeks based on tolerability and response, up to a maintenance dose of 5mg, 7.5mg, 10mg, 12.5mg, or 15mg. Most patients reach their effective dose within 16 to 20 weeks.

How effective is Mounjaro for weight loss?

Mounjaro produces the highest average weight loss of any currently available licensed weight loss medication, with 15 to 22.5 percent body weight reduction over 72 weeks of treatment in clinical trials. The pivotal SURMOUNT-1 trial published in the New England Journal of Medicine (Jastreboff et al., July 2022) randomised 2,539 participants without diabetes to tirzepatide or placebo and demonstrated 20.9 percent average body weight loss at the 15mg maintenance dose, 19.5 percent at 10mg, and 15 percent at 5mg, compared with 3.1 percent in the placebo group.

For context, that represents approximately:

• 20kg loss in a person starting at 100kg on the 15mg dose

• 17.5kg loss in a person starting at 90kg on the 10mg dose

• 12kg loss in a person starting at 80kg on the 5mg dose

Comparative effectiveness against other licensed weight loss medications:

MedicationMechanismAverage weight lossTrial durationMounjaro (tirzepatide)GLP-1 + GIP dual agonist15 to 22.5%72 weeks (SURMOUNT-1)Wegovy (semaglutide 2.4mg)GLP-1 agonist15 to 17%68 weeks (STEP-1)Ozempic (semaglutide 1mg, off-label)GLP-1 agonist6 to 13%68 weeksSaxenda (liraglutide 3mg)GLP-1 agonist5 to 8%56 weeksOrlistat (Xenical)Fat absorption blocker3 to 6%52 weeks

Real-world results vary substantially. Around 70 to 80 percent of patients respond well to Mounjaro with at least 10 percent weight loss within 6 months. Around 15 to 20 percent are partial responders with 5 to 10 percent loss. A small minority (5 to 10 percent) are non-responders, typically requiring evaluation of dose, adherence, lifestyle factors, or alternative treatment.

Beyond pure weight reduction, Mounjaro produces other measurable health benefits:

• HbA1c reduction of approximately 1.8 to 2.4 percent in patients with type 2 diabetes (clinically meaningful)

• Blood pressure reduction averaging 6 to 8 mmHg systolic

• Triglyceride reduction of approximately 25 percent

• Liver fat reduction of approximately 30 percent (relevant to non-alcoholic fatty liver disease)

• Sleep apnoea improvement in patients with co-existing OSA

These metabolic improvements, combined with weight loss, translate into reduced cardiovascular risk and lower likelihood of progressing from prediabetes to type 2 diabetes.

Want a personalised assessment of likely results? WhatsApp +44 7961 280835 for same-day reply

Am I eligible for Mounjaro?

MHRA licensing for weight management with Mounjaro requires BMI of 30 or above, or BMI of 27 to 30 with at least one weight-related health condition. NICE guidance for NHS access is more restrictive (typically BMI 35+ with conditions, via specialist services only). Private clinics typically prescribe within the MHRA licensed criteria. Some clinics extend prescribing from BMI 25 where benefits outweigh risks and the patient has substantial weight-related health concerns, though this is off-label and requires careful clinical justification.

Weight-related health conditions that support eligibility at BMI 27 to 30:

• High blood pressure (hypertension)

• Type 2 diabetes or prediabetes

• Sleep apnoea (obstructive sleep apnoea)

• Cardiovascular disease (heart attack, stroke, heart failure)

• Dyslipidaemia (high cholesterol or triglycerides)

• Non-alcoholic fatty liver disease (NAFLD)

• Polycystic ovary syndrome (PCOS) with metabolic features

• Osteoarthritis affecting weight-bearing joints

Absolute contraindications mean Mounjaro is not safe to prescribe regardless of weight:

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple endocrine neoplasia syndrome type 2 (MEN-2)

• Hypersensitivity to tirzepatide or any excipient

• Pregnancy or active attempt to conceive

• Breastfeeding

Relative contraindications require careful assessment and may rule out treatment:

• History of pancreatitis

• Severe gastrointestinal disease including gastroparesis

• Diabetic retinopathy with recent worsening

• Severe kidney impairment (CKD stage 4 to 5)

• Severe liver disease

• Active eating disorder including bulimia nervosa

• History of suicidal ideation or active mental health crisis

• Type 1 diabetes (Mounjaro is licensed for type 2 only)

Specific medication interactions require dose review:

• Oral contraceptive pills may have reduced effectiveness during dose escalation

• Insulin and sulphonylureas require dose adjustment when combined with Mounjaro

• Warfarin requires INR monitoring after starting

The eligibility assessment at The Wellness is a structured 30-minute consultation including detailed medical history, medication review, BMI confirmation, blood pressure measurement, and baseline blood tests covering HbA1c, kidney function, liver function, lipid profile, thyroid function, and amylase or lipase. This pre-treatment assessment identifies any contraindications and establishes baseline values for monitoring.

How does Mounjaro compare with Wegovy and Ozempic?

Mounjaro, Wegovy, and Ozempic are all weekly injectable medications affecting the GLP-1 system, but they differ in mechanism, efficacy, indication, and cost. Choosing between them depends on your specific clinical picture, prior medication experience, side effect tolerance, and budget.

When Mounjaro is typically the right choice:

• Highest weight loss target (over 15 percent of body weight)

• Co-existing type 2 diabetes (Mounjaro is licensed for both indications)

• Wegovy non-responders or partial responders

• Patients who can tolerate gastrointestinal side effects

• Budget allows £225+ monthly investment

When Wegovy is typically the right choice:

• Slightly lower weight loss target (10 to 15 percent)

• Better tolerability for GI side effects in some patients

• Longer post-launch safety data preference

• Slightly lower cost

• Patient preference for semaglutide based on prior experience

When Ozempic is typically the right choice:

• Type 2 diabetes is the primary indication (weight loss is secondary)

• Mounjaro is unsuitable due to side effects

• Wegovy is unavailable

• Note: Ozempic is not licensed for weight loss and prescribing it for that purpose is off-label

Other options to be aware of:

• Saxenda (liraglutide): daily injection, lower efficacy (5 to 8 percent), older medication. Mostly superseded by weekly options.

• Compounded semaglutide or tirzepatide: not licensed in the UK and not appropriate for prescribing through regulated channels. The MHRA has issued warnings about unlicensed compounded GLP-1 from non-UK sources.

• Orlistat (Xenical, Alli): oral medication blocking fat absorption, much lower efficacy (3 to 6 percent), available without prescription at lower doses but with significant gastrointestinal side effects.

Need help choosing the right medication? WhatsApp our medical team for a structured consultation

How much does Mounjaro cost in London?

Mounjaro costs in London 2026 range from £120 to £375 per month depending on the provider, dose, and what is included in the headline price. The London market includes online-only pharmacies at the budget end (£120 to £180/month, medication only with minimal clinical input), mid-market doctor-led services (£200 to £300/month, medication plus consultation and monitoring), and clinic services (£300 to £400/month, comprehensive specialist care).

The Wellness Mounjaro pricing (verified April 2026):

Typical first-year cost at The Wellness: approximately £3,200 to £3,800 total covering initial consultation, baseline testing, monthly medication and reviews, and one annual review with comprehensive blood retesting.

Why proper clinical supervision matters more than the lowest price:

Mounjaro is a powerful medication with measurable serious-side-effect risk. The cheapest online pharmacy services typically charge £120 to £180 per month for medication only, with minimal clinical input. They rely on online questionnaires, no examination, no baseline blood tests, no in-person follow-up, and limited communication for side effects. The patient holds all the risk.

The mid-market doctor-led approach we operate at The Wellness charges more because:

• Initial 30-minute consultation with GMC-registered doctor reviewing full medical history

• Baseline blood tests including HbA1c, kidney function, liver function, lipid profile, and thyroid screen

• Monthly clinical review during dose escalation phase, then 3-monthly during maintenance

• Direct WhatsApp access to your treating clinician for side effects or questions

• Side effect management including anti-emetic prescriptions where needed

• Annual comprehensive assessment including repeat blood work

• Continuity with the same doctor across your treatment

The premium end (£300 to £400 per month at hospital-based clinics, weight management physicians) adds dietitian input, exercise physiology, and intensive lifestyle programmes that some patients value but most do not need.

Comparison with London competitors (verified April 2026):

• Mayfair Weight Loss Clinic: Mounjaro from £410/month, online consultation model

• London Slimming Clinic: From £410/month, Dr Mihaela C. (GMC 7099398), online platform

• Phlo Clinic: From £349 first pen, £369/month after, postal delivery model

• Bolt Pharmacy: £250 to £450/month, online questionnaire model

• Joinvoy.com: Subscription model with bundle discounts, doctor-led

• Mounjaro.com (manufacturer direct): NHS price approximately £393/month at list

• Premium private GP services with GLP-1: £375 to £475/month with full clinical care

The Wellness sits at the doctor-led mid-premium position: full clinical care without the consultant-fee markup of weight management physician practices.

Get a personalised pricing quote: WhatsApp +44 7961 280835

What are the side effects of Mounjaro?

Mounjaro side effects are predominantly gastrointestinal and predominantly occur during dose escalation phases. Most settle within 4 to 8 weeks as your body adapts to the medication. Serious side effects are rare but require awareness and prompt response.

Very common side effects (more than 10 percent of patients):

• Nausea (20 to 25 percent): typically worst in first 1 to 2 weeks of each new dose, settling over 3 to 4 weeks. Usually mild to moderate. Anti-emetics (ondansetron, metoclopramide) can be prescribed where troublesome.

• Diarrhoea (15 to 20 percent): typically self-limiting, may require dose pause or temporary reduction.

• Constipation (10 to 15 percent): paradoxically common because gastric emptying slows. Hydration and gentle laxatives where needed.

• Decreased appetite (universal): this is the intended therapeutic effect, but can be problematic if it leads to inadequate nutrition.

• Vomiting (10 percent): persistent vomiting requires dose review.

Common side effects (1 to 10 percent of patients):

• Indigestion and reflux

• Abdominal pain and bloating

• Fatigue, particularly in first few weeks

• Headache

• Dizziness on standing (orthostatic hypotension)

• Hypoglycaemia in patients on insulin or sulphonylureas

• Injection site reactions (redness, mild swelling)

• Hair thinning (typically in patients losing weight rapidly)

• Loss of muscle mass alongside fat (mitigated by adequate protein intake and resistance exercise)

Serious but uncommon side effects (under 1 percent):

• Pancreatitis: severe persistent abdominal pain, sometimes radiating to the back, with nausea and vomiting. Requires immediate cessation of Mounjaro and emergency assessment.

• Gallbladder disease: rapid weight loss is a known risk factor for gallstones. Right upper abdominal pain warrants assessment.

• Acute kidney injury: usually secondary to dehydration from severe gastrointestinal symptoms. Adequate hydration during titration is essential.

• Diabetic retinopathy worsening: in patients with pre-existing diabetic eye disease.

• Severe hypoglycaemia: in patients on insulin or sulphonylureas without dose adjustment.

• Allergic reactions: from local skin reactions to rare systemic anaphylaxis.

Black box warning: Tirzepatide caused thyroid C-cell tumours in rodent studies. Whether this risk translates to humans is uncertain. Mounjaro is contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Mental health considerations: Some patients on GLP-1 medications report mood changes including anxiety or low mood. Causation versus association is debated. The MHRA monitors this signal closely. Pre-existing mental health conditions are not contraindications but warrant careful monitoring.

Side effect management at The Wellness includes:

• Pre-emptive anti-nausea medication available on prescription where indicated

• Dose pause or reduction if side effects are intolerable, with structured re-escalation

• Direct WhatsApp access to your clinician for guidance during side effect episodes

• Annual blood work to detect any biochemical changes early

• Specialist referral if complex side effects develop

Most patients tolerate Mounjaro well after the first 4 to 8 weeks. Around 5 to 10 percent of patients discontinue because of intolerable side effects, with most finding alternative options (Wegovy, Saxenda, lifestyle-only) work better for them.

What does the Mounjaro pathway look like at The Wellness?

The Mounjaro pathway at The Online GP by The Wellness is structured around proper clinical care rather than the cheapest price. Six stages cover initial assessment, treatment initiation, dose titration, maintenance, ongoing review, and long-term planning.

Stage 1: Initial consultation (£150, 30 minutes). Your GMC-registered doctor takes a detailed history covering weight history, prior weight loss attempts, medical conditions, medications, family history, mental health, eating patterns, and goals. Examination includes BMI calculation, blood pressure, basic cardiovascular assessment. Validated questionnaires for eating disorder screening and mental health may be used. By the end, you have a clear understanding of whether Mounjaro is appropriate for you.

Stage 2: Baseline assessment (£295). Blood tests covering HbA1c (diabetes screen), full kidney function, liver function, lipid profile, thyroid function, amylase and lipase (pancreas), full blood count, vitamin D, and any other tests indicated by your history. Results typically within 24 to 48 hours.

Stage 3: Treatment initiation (£225 first month medication). Once eligibility is confirmed and baseline tests are reviewed, you receive a private prescription for Mounjaro 2.5mg KwikPen (4 weeks of starting dose). The medication is dispensed at our partner pharmacy. We provide injection technique training including video demonstration, written instructions, and supplies (sharps bin, alcohol wipes, sharps disposal arrangements).

Stage 4: Dose escalation phase (months 1 to 5). Monthly follow-up consultations during titration to assess response, side effects, weight progress, and any issues. Dose increases by 2.5mg every 4 weeks based on tolerability. Most patients reach their effective maintenance dose between 5mg and 15mg over 16 to 20 weeks. Each appointment is included in the monthly fee.

Stage 5: Maintenance phase (months 6 onwards). Once stable on your maintenance dose, reviews move to every 3 months. Weight loss typically continues for 12 to 18 months from start before plateauing. Annual comprehensive blood retest assesses metabolic improvement and detects any new issues.

Stage 6: Long-term planning (year 2 onwards). After reaching target weight, decisions about continuation, dose reduction, or transition off medication are made based on individual factors. Most patients benefit from ongoing maintenance treatment because stopping typically results in weight regain. Some transition to lower doses for sustained effect at lower cost.

What is included throughout:

• All consultations during dose titration and maintenance

• Direct WhatsApp access to your treating clinician for side effects and questions

• Prescription writing and partner pharmacy dispensing

• Weight tracking and review at each appointment

• Annual blood work review

• Diet and lifestyle guidance integrated into consultations

• Side effect management including supportive prescriptions

• Specialist referral pathways if needed

What is not included (because not appropriate for primary care provision):

• Dietitian consultations (referral provided where indicated)

• Exercise physiology assessment (not typically required for medication-led approach)

• Bariatric surgery evaluation (referral to specialist surgical units where indicated)

• Inpatient management for severe complications

Begin your Mounjaro pathway: WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com

Why choose The Wellness for Mounjaro in London?

The Online GP by The Wellness offers a deliberately structured Mounjaro pathway designed around clinical safety, transparent pricing, and continuity of care. Six elements distinguish our approach from the online-pharmacy model dominating the budget end of the market.

GMC-registered doctors with substantive consultation time. Every patient is seen by a doctor for a full 30-minute initial consultation, not assessed via a 10-minute online questionnaire. This identifies contraindications and tailors the approach to your specific situation. BMA and GMC guidance recommend in-person or video consultation with examination for weight loss medication initiation, which is what we provide.

Marylebone clinic with full diagnostic capability. 10 Portman Square sits two minutes from Baker Street and adjacent to Harley Street. Baseline blood tests, blood pressure monitoring, and clinical examination all happen at the same location, in the same visit. Compare this with online services that require separate phlebotomy bookings at third-party laboratories.

Same-day appointment availability. Most patients book their initial consultation within 1 to 3 days. Pathway from first contact to first dose is typically 1 to 5 days, much faster than NHS specialist weight management services (6 to 18 month waits) and competitive with online services without sacrificing clinical depth.

Multilingual care. GMC-registered doctors fluent in English, Arabic, Spanish, French, and Dutch, supporting our substantial international patient base from the Middle East, Europe, and the Americas. Many international patients combine Mounjaro initiation in London with periodic in-person review and ongoing remote monitoring.

Continuity of care. You see the same doctor throughout your pathway. WhatsApp access between appointments. Clinical record retained securely for the full duration of treatment. This continuity is essential for medications requiring dose titration, side effect management, and long-term review.

MHRA-compliant prescribing. We prescribe within MHRA licensed indications and monitor according to BMA, GMC, and Royal College of Physicians guidance. We do not offer compounded semaglutide or tirzepatide (which is unlicensed in the UK and warned against by MHRA), unverified online medication, or prescriptions without proper assessment.

This is a genuinely premium-but-accessible private weight management service: full clinical care for £225 to £275 per month, equivalent in quality to consultant-led practices charging £350+ but without the consultant-fee markup for cases that do not require consultant input.

Frequently asked questions

Will my private medical insurance cover Mounjaro?

Most UK private medical insurance policies do not cover weight loss medication including Mounjaro, treating it as a lifestyle medication rather than treatment for a disease. However, some policies cover diagnostic consultations and baseline blood tests under "investigation of new or worsening symptoms" particularly where weight is contributing to other conditions like type 2 diabetes, hypertension, or sleep apnoea. Check specific coverage with your insurer before booking. We provide itemised invoices to support claims.

Can I switch to Mounjaro from Wegovy or Ozempic?

Yes. Patients on Wegovy or Ozempic can switch to Mounjaro after specialist assessment, often starting at a higher Mounjaro dose if they are stable on a high semaglutide dose. The transition typically involves stopping the previous GLP-1, waiting 7 to 14 days, then starting Mounjaro at an appropriate dose. We assess each patient individually to determine the safest starting dose. WhatsApp our team if you are considering switching.

Do I need to follow a specific diet on Mounjaro?

Not a specific diet, but adequate protein intake (1 to 1.5g per kg of body weight) is important to preserve muscle mass during rapid weight loss. Hydration is essential to reduce gastrointestinal side effects and prevent kidney issues. Resistance exercise 2 to 3 times weekly helps maintain muscle mass. Most patients naturally eat substantially less due to appetite suppression, so the focus shifts from "eating less" to "eating well within smaller portions."

Can Mounjaro affect my contraception?

Yes. Mounjaro can reduce the effectiveness of oral contraceptive pills, particularly during dose escalation phases due to slowed gastric emptying affecting absorption. We recommend additional contraception (barrier methods, IUD, implant, or injectable contraception) for the first 4 weeks after starting Mounjaro and for 4 weeks after each dose increase. This is important because Mounjaro is contraindicated in pregnancy. Discuss your contraception during your consultation.

Can I drink alcohol on Mounjaro?

Moderate alcohol consumption is not strictly contraindicated, but several considerations matter. Mounjaro slows gastric emptying, which can amplify alcohol effects and produce nausea. Hypoglycaemia risk increases with alcohol in patients on Mounjaro plus other diabetes medications. Many patients naturally find alcohol less appealing due to early satiety and the medication's effect on reward pathways. Total weekly intake should remain within UK guidelines (14 units), with alcohol-free days recommended.

What happens when I stop Mounjaro?

Stopping Mounjaro typically results in gradual weight regain over 12 to 18 months because the underlying biology of appetite regulation returns to baseline. Studies show approximately two-thirds of weight loss is regained within 12 months of stopping. This is why Mounjaro is increasingly viewed as a long-term treatment for chronic weight management, similar to how blood pressure medication is taken long-term. Some patients can transition to lower maintenance doses for ongoing benefit at lower cost.

Is Mounjaro safe long-term?

Currently available data extends to 3 to 5 years for tirzepatide and longer for related GLP-1 medications. Long-term safety data is reassuring overall, with the main concerns being thyroid C-cell tumour risk (theoretical, based on rodent studies, not yet seen in human population data), pancreatitis risk (rare but real), and gallbladder issues (related to rapid weight loss). Ongoing post-market surveillance through the MHRA Yellow Card scheme tracks any emerging signals. We monitor patients with annual blood work and clinical review.

Book your Mounjaro consultation today

Mounjaro is the most effective weight loss medication currently licensed in the UK. With proper clinical care, around 70 to 80 percent of patients lose 10 percent or more of their body weight within 6 months, and 20 to 30 percent achieve 20 percent or more loss over 12 to 18 months. The results are real, the side effects are manageable for most, and the medication is now a mainstream tool in private weight management.

The Online GP by The Wellness offers same-day initial consultations at our Marylebone clinic and via secure video, with GMC-registered doctors, full integrated diagnostics, transparent monthly pricing, and continuity of care through your treatment journey. We do not prescribe Mounjaro from online questionnaires alone, in line with BMA and GMC guidance.

Three ways to book today:

WhatsApp: Message +44 7961 280835 for a same-day reply from our medical team.

Email: team@thewellnesslondon.com for detailed enquiries, insurance questions, or international patient queries.

Phone: 020 3951 3429 to speak directly to our team during clinic hours.

The Wellness, 10 Portman Square, Marylebone, London W1H 6AZ. GMC-registered doctors. Same-day appointments. Doctor-led Mounjaro care from £349/month. The right way to do weight loss medicine.

References and further reading

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, July 2022

Eli Lilly Mounjaro KwikPen Summary of Product Characteristics, MHRA

NICE Technology Appraisal TA1026 (Tirzepatide for managing overweight and obesity)

NICE Technology Appraisal TA875 (Semaglutide for managing overweight and obesity)

MHRA guidance on unlicensed compounded weight loss medications

British Medical Association guidance on private prescribing of weight loss medications

Royal College of Physicians position on obesity as a chronic disease

NHS guidance on weight management medication eligibility

General Pharmaceutical Council standards for online prescribing services

Faculty of Pharmaceutical Medicine guidance on weight loss medication monitoring

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Mounjaro is a prescription-only medication requiring individual medical assessment before initiation. Side effects can be significant and require appropriate clinical management. Pregnancy must be avoided during treatment. The Wellness is a private healthcare clinic with GMC-registered doctors. We prescribe within MHRA licensed indications and monitor according to BMA and GMC guidance.